 |
PDBsum entry 4wnk
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structure of g protein-Coupled receptor kinase 5 in complex with a rationally designed inhibitor.
|
 |
|
Authors
|
 |
K.T.Homan,
H.V.Waldschmidt,
A.Glukhova,
A.Cannavo,
J.Song,
J.Y.Cheung,
W.J.Koch,
S.D.Larsen,
J.J.Tesmer.
|
 |
|
Ref.
|
 |
J Biol Chem, 2015,
290,
20649-20659.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
G protein-coupled receptor kinases (GRKs) regulate cell signaling by initiating
the desensitization of active G protein-coupled receptors. The two most widely
expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus
represent important targets for the development of novel therapeutic drugs. In
the course of a GRK2 structure-based drug design campaign, one inhibitor
(CCG215022) exhibited nanomolar IC50 values against both GRK2 and GRK5 and good
selectivity against other closely related kinases such as GRK1 and PKA.
Treatment of murine cardiomyocytes with CCG215022 resulted in significantly
increased contractility at 20-fold lower concentrations than paroxetine, an
inhibitor with more modest selectivity for GRK2. A 2.4 Å crystal structure of
the GRK5·CCG215022 complex was determined and revealed that the inhibitor binds
in the active site similarly to its parent compound GSK180736A. As designed, its
2-pyridylmethyl amide side chain occupies the hydrophobic subsite of the active
site where it forms three additional hydrogen bonds, including one with the
catalytic lysine. The overall conformation of the GRK5 kinase domain is similar
to that of a previously determined structure of GRK6 in what is proposed to be
its active state, but the C-terminal region of the enzyme adopts a distinct
conformation. The kinetic properties of site-directed mutants in this region are
consistent with the hypothesis that this novel C-terminal structure is
representative of the membrane-bound conformation of the enzyme.
|
 |
|
|
|
|
 |